Conditioning with busulfan, gemcitabine and melphalan – pro
The Busulfan, gemcitaibne, melphalan conditioning regimen is fairly new. It was first developed and reported by Nieto in 2012. The idea was that gemcitabine is designed to disrupt the growth of cancer cells, which may cause cancer cells to die. It may help to increase the effect of busulfan and melphalan on the tumor cells, by not allowing these cells to repair the DNA damage caused by busulfan or melphalan.
The authors concluded that gemcitabine/busulfan/melphalan is a feasible regimen with substantial activity against a range of lymphoid malignancies. This regimen merits further evaluation in phase II and III trials. The sentiment that farther studies are required was repeated in the
2013 ASH poster by the same authors. There is an ongoing study: High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin’s Disease, NCT01200329/Yago Nieto et al, High-Dose Gemcitabine Combined With Busulfan and Melphalan (Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Refractory and Relapsed Myeloma
ASH 2013 Annual Meeting Abstract 3346 (Poster Presentation)
Session: 731. Clinical Allogeneic and Autologous Transplantation – Results: Poster II
Time: Sunday, December 8, 2013, 6:30 PM-8:30 PM
Location: Hall G (Ernest N. Morial Convention Center)